IDH1 and central nervous system cancer: In addition, neutralizing neutrophils by using a monoclonal antibody against Ly6G resulted in increased survival of an IDH1–wild-type (WT) glioma model, but not an IDH1-mutant (MUT) PDGFB-driven glioma mouse model.